Northwestern Mutual Wealth Management CO Biotechnology

Northwestern Mutual Wealth Management CO

$112 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
NVO Novo Nordisk A S	$199B	$52.2 Million 0.05% of portfolio	438,233	Q3 2024 Reduced 2.29%
VRTX Vertex Pharmaceuticals Inc	$113B	$5.77 Million 0.01% of portfolio	12,397	Q3 2024 Reduced 22.24%
REGN Regeneron Pharmaceuticals, Inc.	$72.4B	$4.17 Million 0.0% of portfolio	3,969	Q3 2024 Added 3.87%
PTGX Protagonist Therapeutics, Inc	$1.85B	$3.55 Million 0.0% of portfolio	78,894	Q3 2024 Reduced 50.0%
KROS Keros Therapeutics, Inc.	$305M	$1.03 Million 0.0% of portfolio	17,674	Q3 2024 New
BMRN Biomarin Pharmaceutical Inc	$11.5B	$1.02 Million 0.0% of portfolio	14,527	Q3 2024 Reduced 96.32%
MRNA Moderna, Inc.	$16.2B	$746,000 0.0% of portfolio	11,176	Q3 2024 Reduced 6.34%
INCY Incyte Corp	$16.1B	$482,000 0.0% of portfolio	7,306	Q3 2024 Reduced 21.86%
TGTX Tg Therapeutics, Inc.	$4.54B	$468,000 0.0% of portfolio	20,025	Q3 2024 Added 3.76%
IONS Ionis Pharmaceuticals Inc	$4.93B	$451,000 0.0% of portfolio	11,263	Q3 2024 Added 0.45%
CRSP Crispr Therapeutics Ag	$3.39B	$219,000 0.0% of portfolio	4,670	Q3 2024 Added 1.39%
JAZZ Jazz Pharmaceuticals PLC	$7.65B	$215,000 0.0% of portfolio	1,935	Q3 2024 Added 1.68%
XENE Xenon Pharmaceuticals Inc.	$2.49B	$196,000 0.0% of portfolio	5,000	Q4 2022 New
TECH Bio Techne Corp	$3.02B	$188,000 0.0% of portfolio	2,359	Q3 2024 Added 23.06%
UTHR United Therapeutics Corp	$16.9B	$146,000 0.0% of portfolio	408	Q3 2024 Added 41.18%
ALNY Alnylam Pharmaceuticals, Inc.	$34.3B	$143,000 0.0% of portfolio	523	Q3 2024 Reduced 12.25%
RPRX Royalty Pharma PLC	$13.6B	$103,000 0.0% of portfolio	3,669	Q3 2024 Added 22,831.25%
VCEL Vericel Corp	$2.71B	$84,000 0.0% of portfolio	2,005	Q3 2024 Reduced 51.19%
BPMC Blueprint Medicines Corp	$6.86B	$83,000 0.0% of portfolio	899	Q3 2024 Added 2.04%
ETNB 89bio, Inc.	$331M	$60,000 0.0% of portfolio	8,200	Q2 2024 New
NTLA Intellia Therapeutics, Inc.	$835M	$60,000 0.0% of portfolio	2,956	Q3 2024 Added 6.6%
LGND Ligand Pharmaceuticals Inc	$1.94B	$58,000 0.0% of portfolio	583	Q3 2024 Added 3.0%
PTCT Ptc Therapeutics, Inc.	$3.32B	$53,000 0.0% of portfolio	1,453	Q3 2023 Reduced 1.82%
EXEL Exelixis, Inc.	$10.4B	$43,000 0.0% of portfolio	1,676	Q3 2024 Added 67.6%
RXRX Recursion Pharmaceuticals, Inc.	$1.32B	$35,000 0.0% of portfolio	5,399	Q3 2024 New
VCYT Veracyte, Inc.	$3.14B	$34,000 0.0% of portfolio	1,015	Q3 2024 Added 1.5%
AXSM Axsome Therapeutics, Inc.	$4.42B	$30,000 0.0% of portfolio	345	Q3 2024 Added 2.99%
SRPT Sarepta Therapeutics, Inc.	$10.2B	$26,000 0.0% of portfolio	209	Q3 2024 Reduced 16.4%
BNTX Bio N Tech Se	$28.7B	$24,000 0.0% of portfolio	205	Q3 2024 Added 102.97%
IOVA Iovance Biotherapeutics, Inc.	$986M	$20,000 0.0% of portfolio	2,189	Q3 2024 Added 16.44%
MRUS Merus N.V.	$1.89B	$20,000 0.0% of portfolio	404	Q2 2023 Reduced 49.5%
HALO Halozyme Therapeutics, Inc.	$7.77B	$19,000 0.0% of portfolio	343	Q3 2024 Added 69.8%
ARGX Argenx Se	$35.9B	$18,000 0.0% of portfolio	35	Q3 2024 Added 59.09%
APLS Apellis Pharmaceuticals, Inc.	$3.3B	$17,000 0.0% of portfolio	600	Q4 2023 New
CVAC Cure Vac N.V.	$722M	$13,000 0.0% of portfolio	4,515	Q1 2024 Added 8,261.11%
RVPH Reviva Pharmaceuticals Holdings, Inc.	$39M	$13,000 0.0% of portfolio	9,299	Q4 2021 New
GERN Geron Corp	$1.14B	$9,000 0.0% of portfolio	2,000	Q1 2024 Reduced 11.7%
CHRS Coherus Bio Sciences, Inc.	$96.4M	$7,000 0.0% of portfolio	7,350	Q1 2024 New
EYPT Eye Point Pharmaceuticals, Inc.	$294M	$7,000 0.0% of portfolio	1,000	Q1 2024 New
MRVI Maravai Lifesciences Holdings, Inc.	$739M	$7,000 0.0% of portfolio	888	Q3 2024 New
PCVX Vaxcyte, Inc.	$5.32B	$7,000 0.0% of portfolio	67	Q3 2024 New
MDXG Mimedx Group, Inc.	$999M	$5,000 0.0% of portfolio	1,000	Q3 2024 Reduced 50.0%
ARWR Arrowhead Pharmaceuticals, Inc.	$2.2B	$4,000 0.0% of portfolio	234	Q4 2023 Reduced 55.34%
BGNE Bei Gene, Ltd.	$22.7B	$4,000 0.0% of portfolio	20	Q3 2024 Reduced 56.52%
BCRX Biocryst Pharmaceuticals Inc	$1.42B	$4,000 0.0% of portfolio	527	Q3 2024 New
GMAB Genmab A/S	$13.9B	$4,000 0.0% of portfolio	166	Q3 2024 Reduced 60.76%
INSM Insmed Inc	$10.6B	$4,000 0.0% of portfolio	55	Q3 2024 New
NVAX Novavax Inc	$721M	$4,000 0.0% of portfolio	389	Q3 2024 Reduced 10.98%
RVNC Revance Therapeutics, Inc.	$212M	$4,000 0.0% of portfolio	1,700	Q3 2024 Reduced 48.52%
ACXP Acurx Pharmaceuticals, Inc.	$10.1M	$3,000 0.0% of portfolio	1,636	Q2 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northwestern Mutual Wealth Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Northwestern Mutual Wealth Management CO with notifications on news.